Skip to main content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener klinische Wochenschrift 2/2016

01.04.2016 | leitlinien für die praxis

Diagnose, Therapie und Verlaufskontrolle der diabetischen Augenerkrankung

verfasst von: Stephan Radda, Matthias Bolz, Stefan Egger, Vanessa Gasser-Steiner, Martina Kralinger, Stefan Mennel, Christoph Scholda, Ulrike Stolba, Andreas Wedrich, Katharina Krepler

Erschienen in: Wiener klinische Wochenschrift | Sonderheft 2/2016

Einloggen, um Zugang zu erhalten
share
TEILEN

Zusammenfassung

Diabetes mellitus kann diabetische Retinopathie, diabetisches Makulaödem, Optikusneuropathie, Katarakt und Fehlfunktionen der äußeren Augenmuskeln verursachen. Die Inzidenz dieser Spätschäden korreliert mit der Dauer des Diabetes und mit dem Grad der metabolischen Kontrolle. Die Empfehlungen der Österreichischen Diabetesgesellschaft für Diagnose, Therapie und Nachkontrolle werden übersichtsweise und bezogen auf die jeweiligen Stadien der diabetischen Augenerkrankung präsentiert.
Literatur
1.
Zurück zum Zitat Khadem J, Buzney S, Alich K. Practice patterns in diabetic retinopathy: part 1: analysis of retinopathy follow-up. Arch Ophthalmol. 1999;117:815–20. CrossRefPubMed Khadem J, Buzney S, Alich K. Practice patterns in diabetic retinopathy: part 1: analysis of retinopathy follow-up. Arch Ophthalmol. 1999;117:815–20. CrossRefPubMed
2.
Zurück zum Zitat McCarty C, Taylor K, McKay R, et al. Diabetic retinopathy: effects of national guidelines on the referral, examination and treatment practices of ophthalmologists and optometrists. Clin Experiment Ophthalmol. 2001;29:52–8. CrossRefPubMed McCarty C, Taylor K, McKay R, et al. Diabetic retinopathy: effects of national guidelines on the referral, examination and treatment practices of ophthalmologists and optometrists. Clin Experiment Ophthalmol. 2001;29:52–8. CrossRefPubMed
3.
Zurück zum Zitat Wilkinson C, Ferris F, Klein R, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110:1677–82. CrossRefPubMed Wilkinson C, Ferris F, Klein R, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110:1677–82. CrossRefPubMed
4.
Zurück zum Zitat Hazin R, Colyer M, Lum F, et al. Revisiting Diabetes 2000: challenges in establishing nationwide diabetic retinopathy prevention programs. Am J Ophthalmol. 2011;152:723–9. CrossRefPubMed Hazin R, Colyer M, Lum F, et al. Revisiting Diabetes 2000: challenges in establishing nationwide diabetic retinopathy prevention programs. Am J Ophthalmol. 2011;152:723–9. CrossRefPubMed
5.
Zurück zum Zitat Hammes H, Lemmen K Diagnostik, Therapie und Verlaufskontrolle der diabetischen Retinopathie und Makulopathie. Diabetes Stoffwechsel. 2002;11(Suppl 2):15–6. Hammes H, Lemmen K Diagnostik, Therapie und Verlaufskontrolle der diabetischen Retinopathie und Makulopathie. Diabetes Stoffwechsel. 2002;11(Suppl 2):15–6.
6.
Zurück zum Zitat Klein R, Klein BE, Moss SE. Epidemiology of proliferative diabetic retinopathy. Diabetes Care. 1992;15:1875–91. CrossRefPubMed Klein R, Klein BE, Moss SE. Epidemiology of proliferative diabetic retinopathy. Diabetes Care. 1992;15:1875–91. CrossRefPubMed
7.
Zurück zum Zitat Zhang L, Krzentowski G, Albert A, et al. Risk of developing retinopathy in Diabetes Control and Complications Trial type 1 diabetic patients with good or poor metabolic control. Diabetes Care. 2001;24:1275–9. CrossRefPubMed Zhang L, Krzentowski G, Albert A, et al. Risk of developing retinopathy in Diabetes Control and Complications Trial type 1 diabetic patients with good or poor metabolic control. Diabetes Care. 2001;24:1275–9. CrossRefPubMed
8.
Zurück zum Zitat Stratton I, Kohner E, Aldington S, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 yrs from diagnosis. Diabetologia. 2001;44:156–63. CrossRefPubMed Stratton I, Kohner E, Aldington S, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 yrs from diagnosis. Diabetologia. 2001;44:156–63. CrossRefPubMed
9.
Zurück zum Zitat Murphy RP, Nanda M, Plotnick L, et al. The relationship of puberty to diabetic retinopathy. Arch Ophthalmol. 1990;108(2):215–8. CrossRefPubMed Murphy RP, Nanda M, Plotnick L, et al. The relationship of puberty to diabetic retinopathy. Arch Ophthalmol. 1990;108(2):215–8. CrossRefPubMed
10.
Zurück zum Zitat Effect of pregnancy on microvascular complications in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes Care. 2000;23:1084–91. Effect of pregnancy on microvascular complications in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes Care. 2000;23:1084–91.
11.
Zurück zum Zitat Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol. 1998;116:874–86. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol. 1998;116:874–86.
12.
Zurück zum Zitat Orchard T, Forrest K, Kuller L, et al. Lipid and blood pressure treatment goals for type 1 diabetes: 10-year incidence data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care. 2001;24:1053–9. CrossRefPubMed Orchard T, Forrest K, Kuller L, et al. Lipid and blood pressure treatment goals for type 1 diabetes: 10-year incidence data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care. 2001;24:1053–9. CrossRefPubMed
13.
Zurück zum Zitat Sen K, Misra A, Kumar A, et al. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin Pract. 2002;56:1–11. CrossRefPubMed Sen K, Misra A, Kumar A, et al. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin Pract. 2002;56:1–11. CrossRefPubMed
14.
Zurück zum Zitat UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703–13. CrossRefPubMedCentral UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703–13. CrossRefPubMedCentral
15.
Zurück zum Zitat Nasr C, Hoogwerf B, Faiman C, et al. United Kingdom Prospective Diabetes Study (UKPDS). Effects of glucose and blood pressure control on complications of type 2 diabetes mellitus. Cleve Clin J Med. 1999;66:247–53. CrossRefPubMed Nasr C, Hoogwerf B, Faiman C, et al. United Kingdom Prospective Diabetes Study (UKPDS). Effects of glucose and blood pressure control on complications of type 2 diabetes mellitus. Cleve Clin J Med. 1999;66:247–53. CrossRefPubMed
16.
Zurück zum Zitat Davis M, Fisher M, Gangnon R, et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: early Treatment Diabetic Retinopathy Study Report Number 18. Invest Ophthalmol Vis Sci. 1998;39:233–52. PubMed Davis M, Fisher M, Gangnon R, et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: early Treatment Diabetic Retinopathy Study Report Number 18. Invest Ophthalmol Vis Sci. 1998;39:233–52. PubMed
17.
Zurück zum Zitat Kinyoun J, Barton F, Fisher M, et al. Detection of diabetic macular edema. Ophthalmoscopy versus photography – Early Treatment Diabetic Retinopathy Study Report Number 5. The ETDRS Research Group. Ophthalmology. 1989;96:746–50. CrossRefPubMed Kinyoun J, Barton F, Fisher M, et al. Detection of diabetic macular edema. Ophthalmoscopy versus photography – Early Treatment Diabetic Retinopathy Study Report Number 5. The ETDRS Research Group. Ophthalmology. 1989;96:746–50. CrossRefPubMed
18.
Zurück zum Zitat Gonzalez Villalpando C, Gonzalez Villalpando ME, Martinez Diaz S, et al. A diabetic retinopathy screening program as a strategy for blindness prevention. Arch Med Res. 1997;28:129–35. PubMed Gonzalez Villalpando C, Gonzalez Villalpando ME, Martinez Diaz S, et al. A diabetic retinopathy screening program as a strategy for blindness prevention. Arch Med Res. 1997;28:129–35. PubMed
19.
Zurück zum Zitat Bolz M, Schmidt-Erfurth U, Deak G, et al. Optical coherence tomographic hyperreflective foci: a morphologic sign of lipid extravasation in diabetic macular edema. Ophthalmology. 2009;116:914–20. CrossRefPubMed Bolz M, Schmidt-Erfurth U, Deak G, et al. Optical coherence tomographic hyperreflective foci: a morphologic sign of lipid extravasation in diabetic macular edema. Ophthalmology. 2009;116:914–20. CrossRefPubMed
20.
Zurück zum Zitat Baskin DE. Optical coherence tomography in diabetic macular edema. Curr Opin Ophthalmol. 2010;21:172–7. CrossRefPubMed Baskin DE. Optical coherence tomography in diabetic macular edema. Curr Opin Ophthalmol. 2010;21:172–7. CrossRefPubMed
21.
Zurück zum Zitat Tangelder GJ, Van der Heijde RG, Polak BC, et al. Precision and reliability of retinal thickness measurements in foveal and extrafoveal areas of healthy and diabetic eyes. Invest Ophthalmol Vis Sci. 2008;49:2627–34. CrossRefPubMed Tangelder GJ, Van der Heijde RG, Polak BC, et al. Precision and reliability of retinal thickness measurements in foveal and extrafoveal areas of healthy and diabetic eyes. Invest Ophthalmol Vis Sci. 2008;49:2627–34. CrossRefPubMed
22.
Zurück zum Zitat Browning DJ, Fraser CM. The predictive value of patient and eye characteristics on the course of subclinical diabetic macular edema. Am J Ophthalmol. 2008;145:149–54. CrossRefPubMed Browning DJ, Fraser CM. The predictive value of patient and eye characteristics on the course of subclinical diabetic macular edema. Am J Ophthalmol. 2008;145:149–54. CrossRefPubMed
23.
Zurück zum Zitat Bolz M, Ritter M, Schneider M, et al. A systematic correlation of angiography and high-resolution optical coherence tomography in diabetic macular edema. Ophthalmology. 2009;116:66–72. CrossRefPubMed Bolz M, Ritter M, Schneider M, et al. A systematic correlation of angiography and high-resolution optical coherence tomography in diabetic macular edema. Ophthalmology. 2009;116:66–72. CrossRefPubMed
24.
Zurück zum Zitat Fluorescein angiographic risk factors for progression of diabetic retinopathy. ETDRS report number 13. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991;98 Suppl 5:834–40. Fluorescein angiographic risk factors for progression of diabetic retinopathy. ETDRS report number 13. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991;98 Suppl 5:834–40.
25.
Zurück zum Zitat Pandit RJ, Taylor R. Quality assurance in screening for sight-threatening diabetic retinopathy. Diabet Med. 2002;19:285–91. CrossRefPubMed Pandit RJ, Taylor R. Quality assurance in screening for sight-threatening diabetic retinopathy. Diabet Med. 2002;19:285–91. CrossRefPubMed
26.
Zurück zum Zitat Kuo HK, Hsieh HH, Liu RT. Screening for diabetic retinopathy by one-field, non-mydriatic, 45 degrees digital photography is inadequate. Ophthalmologica. 2005;219:292–6. CrossRefPubMed Kuo HK, Hsieh HH, Liu RT. Screening for diabetic retinopathy by one-field, non-mydriatic, 45 degrees digital photography is inadequate. Ophthalmologica. 2005;219:292–6. CrossRefPubMed
27.
Zurück zum Zitat Case reports to accompany Early Treatment Diabetic Retinopathy Study Reports 3 and 4. The Early Treatment Diabetic Retinopathy Study Research Group. Int Ophthalmol Clin. 1987;27:273–333. Case reports to accompany Early Treatment Diabetic Retinopathy Study Reports 3 and 4. The Early Treatment Diabetic Retinopathy Study Research Group. Int Ophthalmol Clin. 1987;27:273–333.
28.
Zurück zum Zitat Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991;5:823–33. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991;5:823–33.
29.
30.
Zurück zum Zitat Fong D, Ferris F, Davis M, et al. Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. Am J Ophthalmol. 1999;127(2):137–41. CrossRefPubMed Fong D, Ferris F, Davis M, et al. Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. Am J Ophthalmol. 1999;127(2):137–41. CrossRefPubMed
31.
Zurück zum Zitat Antcliff R, Marshall J. The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol. 1999;14:223–32. CrossRefPubMed Antcliff R, Marshall J. The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol. 1999;14:223–32. CrossRefPubMed
32.
Zurück zum Zitat CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA. 2002;287:2542–51. CrossRef CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA. 2002;287:2542–51. CrossRef
33.
Zurück zum Zitat Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1987;94:761–74. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1987;94:761–74.
34.
Zurück zum Zitat Kohner E, Stratton I, Aldington S, et al. Relationship between the severity of retinopathy and progression to photocoagulation in patients with Type 2 diabetes mellitus in the UKPDS (UKPDS 52). Diabet Med. 2001;18:178–84. CrossRefPubMed Kohner E, Stratton I, Aldington S, et al. Relationship between the severity of retinopathy and progression to photocoagulation in patients with Type 2 diabetes mellitus in the UKPDS (UKPDS 52). Diabet Med. 2001;18:178–84. CrossRefPubMed
35.
Zurück zum Zitat The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial. Arch Ophthalmol. 1995;113:36–51. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial. Arch Ophthalmol. 1995;113:36–51.
36.
Zurück zum Zitat Squirrell D, Bhola R, Bush J, et al. A prospective, case controlled study of the natural history of diabetic retinopathy and maculopathy after uncomplicated phacoemulsification cataract surgery in patients with type 2 diabetes. Br J Ophthalmol. 2002;86:565–71. CrossRefPubMedPubMedCentral Squirrell D, Bhola R, Bush J, et al. A prospective, case controlled study of the natural history of diabetic retinopathy and maculopathy after uncomplicated phacoemulsification cataract surgery in patients with type 2 diabetes. Br J Ophthalmol. 2002;86:565–71. CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Flesner P, Sander B, Henning V, et al. Cataract surgery on diabetic patients. A prospective evaluation of risk factors and complications. Acta Ophthalmol Scand. 2002;80:19–24. CrossRefPubMed Flesner P, Sander B, Henning V, et al. Cataract surgery on diabetic patients. A prospective evaluation of risk factors and complications. Acta Ophthalmol Scand. 2002;80:19–24. CrossRefPubMed
38.
Zurück zum Zitat Chung J, Kim MY, Kim HS, et al. Effect of cataract surgery on the progression of diabetic retinopathy. J Cataract Refract Surg. 2002;28:626–30. CrossRefPubMed Chung J, Kim MY, Kim HS, et al. Effect of cataract surgery on the progression of diabetic retinopathy. J Cataract Refract Surg. 2002;28:626–30. CrossRefPubMed
39.
Zurück zum Zitat Cunha-Vaz J. Lowering the risk of visual impairment and blindness. Diabet Med. 1998;15(Suppl 4):S47–50. CrossRefPubMed Cunha-Vaz J. Lowering the risk of visual impairment and blindness. Diabet Med. 1998;15(Suppl 4):S47–50. CrossRefPubMed
40.
Zurück zum Zitat Aiello LP, Beck RW, Bressler NM, et al. Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema. Ophthalmology. 2011;118:e5–14. CrossRefPubMedPubMedCentral Aiello LP, Beck RW, Bressler NM, et al. Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema. Ophthalmology. 2011;118:e5–14. CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117:1064–77. CrossRefPubMedPubMedCentral Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117:1064–77. CrossRefPubMedPubMedCentral
42.
Zurück zum Zitat Nguyen QD, Shah SM, Khwaja AA, et al. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology. 2010;117:2146–51. CrossRefPubMed Nguyen QD, Shah SM, Khwaja AA, et al. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology. 2010;117:2146–51. CrossRefPubMed
43.
Zurück zum Zitat Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33:2399–405. CrossRefPubMedPubMedCentral Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33:2399–405. CrossRefPubMedPubMedCentral
44.
Zurück zum Zitat Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011;118:609–14. CrossRefPubMedPubMedCentral Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011;118:609–14. CrossRefPubMedPubMedCentral
45.
Zurück zum Zitat Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789–801. CrossRefPubMed Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789–801. CrossRefPubMed
47.
Zurück zum Zitat Korobelnik JF, Do DV, Schmidt-Erfurth U, Boyer DS, Holz FG, Heier JS, Midena E, Kaiser PK, Terasaki H, Marcus DM, Nguyen QD, Jaffe GJ, Slakter JS, Simader C, Soo Y, Schmelter T, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Zeitz O, Metzig C, Brown DM. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121(11):2247–54. doi: 10.​1016/​j.​ophtha.​2014.​05.​006. CrossRefPubMed Korobelnik JF, Do DV, Schmidt-Erfurth U, Boyer DS, Holz FG, Heier JS, Midena E, Kaiser PK, Terasaki H, Marcus DM, Nguyen QD, Jaffe GJ, Slakter JS, Simader C, Soo Y, Schmelter T, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Zeitz O, Metzig C, Brown DM. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121(11):2247–54. doi: 10.​1016/​j.​ophtha.​2014.​05.​006. CrossRefPubMed
48.
Zurück zum Zitat Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372:1193–203. doi: 10.​1056/​NEJMoa1414264. CrossRef Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372:1193–203. doi: 10.​1056/​NEJMoa1414264. CrossRef
49.
Zurück zum Zitat Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615–25. CrossRefPubMed Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615–25. CrossRefPubMed
50.
Zurück zum Zitat Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, Li XY, Cui H, Hashad Y, Whitcup SM, Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121:1904–14. doi: 10.​1016/​j.​ophtha.​2014.​04.​024. CrossRefPubMed Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, Li XY, Cui H, Hashad Y, Whitcup SM, Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121:1904–14. doi: 10.​1016/​j.​ophtha.​2014.​04.​024. CrossRefPubMed
51.
Zurück zum Zitat Campochiaro PA, Brown DM, Pearson A, Ciulla T, Boyer D, Holz FG, Tolentino M, Gupta A, Duarte L, Madreperla S, Gonder J, Kapik B, Billman K, Kane FE. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118:626–35.e2. doi: 10.​1016/​j.​ophtha.​2010.​12.​028. CrossRefPubMed Campochiaro PA, Brown DM, Pearson A, Ciulla T, Boyer D, Holz FG, Tolentino M, Gupta A, Duarte L, Madreperla S, Gonder J, Kapik B, Billman K, Kane FE. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118:626–35.e2. doi: 10.​1016/​j.​ophtha.​2010.​12.​028. CrossRefPubMed
52.
Zurück zum Zitat Preliminary report on effects of photocoagulation therapy. The Diabetic Retinopathy Study Research Group. Am J Ophthalmol. 1976;81:383–96. Preliminary report on effects of photocoagulation therapy. The Diabetic Retinopathy Study Research Group. Am J Ophthalmol. 1976;81:383–96.
53.
Zurück zum Zitat Techniques for scatter and local photocoagulation treatment of diabetic retinopathy: early Treatment Diabetic Retinopathy Study Report no. 3. The Early Treatment Diabetic Retinopathy Study Research Group. Int Ophthalmol Clin. 1987;27:254–64. Techniques for scatter and local photocoagulation treatment of diabetic retinopathy: early Treatment Diabetic Retinopathy Study Report no. 3. The Early Treatment Diabetic Retinopathy Study Research Group. Int Ophthalmol Clin. 1987;27:254–64.
54.
Zurück zum Zitat Googe J, Brucker AJ, Bressler NM, et al. Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina. 2011;31:1009–27. CrossRefPubMed Googe J, Brucker AJ, Bressler NM, et al. Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina. 2011;31:1009–27. CrossRefPubMed
55.
Zurück zum Zitat Ferris F. Early photocoagulation in patients with either type I or type II diabetes. Trans Am Ophthalmol Soc. 1996;94:505–37. PubMedPubMedCentral Ferris F. Early photocoagulation in patients with either type I or type II diabetes. Trans Am Ophthalmol Soc. 1996;94:505–37. PubMedPubMedCentral
56.
Zurück zum Zitat Bodanowitz S, Hesse L, Weinand F, et al. Vitrectomy in diabetic patients with a blind fellow eye. Acta Ophthalmol Scand. 1996;74:84–8. CrossRefPubMed Bodanowitz S, Hesse L, Weinand F, et al. Vitrectomy in diabetic patients with a blind fellow eye. Acta Ophthalmol Scand. 1996;74:84–8. CrossRefPubMed
57.
Zurück zum Zitat Filho JA, Messias A, Almeida FP, et al. Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy. Acta Ophthalmol. 2011;89:567–72. CrossRef Filho JA, Messias A, Almeida FP, et al. Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy. Acta Ophthalmol. 2011;89:567–72. CrossRef
58.
Zurück zum Zitat Kohner EM, Barry PJ. Prevention of blindness in diabetic retinopathy. Diabetologia. 1984;26:173–9. CrossRefPubMed Kohner EM, Barry PJ. Prevention of blindness in diabetic retinopathy. Diabetologia. 1984;26:173–9. CrossRefPubMed
59.
Zurück zum Zitat Rand LI, Prud’homme GJ, Ederer F, et al. Factors influencing the development of visual loss in advanced diabetic retinopathy. Diabetic Retinopathy Study (DRS) Report No. 10. Invest Ophthalmol Vis Sci. 1985;26:983–91. PubMed Rand LI, Prud’homme GJ, Ederer F, et al. Factors influencing the development of visual loss in advanced diabetic retinopathy. Diabetic Retinopathy Study (DRS) Report No. 10. Invest Ophthalmol Vis Sci. 1985;26:983–91. PubMed
60.
Zurück zum Zitat Dogru M, Nakamura M, Inoue M, et al. Long-term visual outcome in proliferative diabetic retinopathy patients after panretinal photocoagulation. Jpn J Ophthalmol. 1999;43:217–24. CrossRefPubMed Dogru M, Nakamura M, Inoue M, et al. Long-term visual outcome in proliferative diabetic retinopathy patients after panretinal photocoagulation. Jpn J Ophthalmol. 1999;43:217–24. CrossRefPubMed
Metadaten
Titel
Diagnose, Therapie und Verlaufskontrolle der diabetischen Augenerkrankung
verfasst von
Stephan Radda
Matthias Bolz
Stefan Egger
Vanessa Gasser-Steiner
Martina Kralinger
Stefan Mennel
Christoph Scholda
Ulrike Stolba
Andreas Wedrich
Katharina Krepler
Publikationsdatum
01.04.2016
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe Sonderheft 2/2016
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-016-0983-z

Weitere Artikel der Sonderheft 2/2016

Wiener klinische Wochenschrift 2/2016 Zur Ausgabe

leitlinien für die praxis

Diabetischer Fuß